Island Pharmaceuticals Ltd
Island Pharmaceuticals Limited is an Australia-based drug repurposing company.
The business
Island Pharmaceuticals Limited is an Australia-based drug repurposing company. The Company is focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Its lead asset is ISLA-101, a drug with a safety profile being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. ISLA-101 has been shown to have activity against all four strains of dengue virus as well as other flaviviruses such as Zika virus, West Nile virus, and Yellow Fever virus, as well as Chikungunya virus. While ISLA-101 is an oral formulation, the Company is also considering alternative formulations, including a long-acting oral formulation and intravenous formulations for severe dengue infections. The Company operates a single segment, being research and development activities principally in the geographic regions of Australia and the United States. Its subsidiary is Isla Pharmaceuticals Inc.
Small Caps Research
No research on Island Pharmaceuticals Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise ILA based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Island Pharmaceuticals Expedites Purchase of Galidesivir RNA Anti-Viral Program
Anti-viral drug development company Island Pharmaceuticals (ASX: ILA) has expedited its US$550,000 acquisition of the galidesivir anti-viral program from US-based BioCryst Pharmaceuticals. The move followed “considerable confidence” that Island gained in the asset from an extensive due diligence process that included a dataset review and collaboration with consultants to define a pathway for regulatory approvals. […]
Island Pharmaceuticals reports positive anti-viral results from Phase 2a of dengue fever trial
Island Pharmaceuticals (ASX: ILA) has announced that lead candidate ISLA-101 has shown positive safety and antiviral activity in a Phase 2a cohort of its PROTECT Phase 2a/b trial into the treatment of dengue fever. The trial is assessing whether the drug can prevent or reduce viremia (a medical condition where viruses enter the bloodstream) and […]
Weekly wrap: rumours of wars send the ASX 200 tumbling
It is the Bible that talks about not being alarmed by “wars and rumours of wars” but Australian share market investors weren’t quite so sanguine, pushing down the ASX 200 sharply. By the close of trade on Friday 55.2 points or 0.7% had been erased from the ASX 200 as the reality of a worsening […]
Island Pharmaceuticals initiates dosing of Phase2a patients in ISLA-101 dengue fever trial
Antiviral drug development company Island Pharmaceuticals (ASX: ILA) has initiated the dosing of all subjects in the Phase 2a component of its ISLA-101 Phase 2a/b PROTECT clinical trial to treat dengue fever. The trial capitalises on years of research by the US Army to develop a live attenuated strain of the dengue virus, which can […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.